Esreboxetine

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Esreboxetine
Esreboxetine.png
Systematic (IUPAC) name
(2S)-2-[(S)-(2-ethoxyphenoxy)phenylmethyl]morpholine
Clinical data
Legal status Uncontrolled
Routes Oral
Identifiers
CAS number 98819-76-2 YesY
ATC code None
PubChem CID 65856
ChemSpider 59268 N
UNII L8S50ZY490 YesY
KEGG D09340 YesY
Chemical data
Formula C19H23NO3 
Mol. mass 313.391 g/mol
 N (what is this?)  (verify)

Esreboxetine is a selective norepinephrine reuptake inhibitor which was under development by Pfizer for the treatment of neuropathic pain and fibromyalgia but failed to show significant benefit over currently available medications and was discontinued.[1][2][3][4] It is the (+)-(S,S)-enantiomer of reboxetine and is even more selective in comparison.[1][5]

However, recently it has been shown that esreboxetine could be effective in fibromyalgia patients.[6]

See also[edit]

References[edit]

  1. ^ a b Matilda Bingham; Napier, Susan Jolliffe (2009). Transporters as Targets for Drugs (Topics in Medicinal Chemistry). Berlin: Springer. ISBN 3-540-87911-0. 
  2. ^ Rao SG (October 2009). "Current progress in the pharmacological therapy of fibromyalgia". Expert Opinion on Investigational Drugs 18 (10): 1479–93. doi:10.1517/13543780903203771. PMID 19732029. 
  3. ^ "Search of: esreboxetine - List Results - ClinicalTrials.gov". 
  4. ^ "Musculoskeletal Report: Pfizer Stops Work on Esreboxetine for FM". 
  5. ^ Fish, P. V.; MacKenny, M.; Bish, G.; Buxton, T.; Cave, R.; Drouard, D.; Hoople, D.; Jessiman, A.; Miller, D.; Pasquinet, C.; Patel, B.; Reeves, K.; Ryckmans, T.; Skerten, M.; Wakenhut, F. (2009). "Enantioselective synthesis of (R)- and (S)-N-Boc-morpholine-2-carboxylic acids by enzyme-catalyzed kinetic resolution: application to the synthesis of reboxetine analogs". Tetrahedron Letters 50 (4): 389. doi:10.1016/j.tetlet.2008.11.025.  edit
  6. ^ Arnold, L. M., Hirsch, I., Sanders, P., Ellis, A. and Hughes, B. (2012), Safety and efficacy of esreboxetine in patients with fibromyalgia: A fourteen-week, randomized, double-blind, placebo-controlled, multicenter clinical trial. Arthritis & Rheumatism, 64: 2387–2397. doi: 10.1002/art.34390